Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: A retrospective observational multicenter study on 15 patients

Clinical Rheumatology

Volumn 33, Issue 2, 2014, Pages 273-276

  Costa, Luisa ^a,b   Caso, Francesco ^b   Atteno, Mariangela ^a   Giannitti, Chiara ^c   Spadaro, Antonio ^d   Ramonda, Roberta ^b   Vezzù, Maristella ^b   Del Puente, Antonio ^a   Morisco, Filomena ^a   Fiocco, Ugo ^b   Galeazzi, Mauro ^c   Punzi, Leonardo ^b   Scarpa, Raffaele ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Adalimumab; Anti TNF ; Etanercept; HCV infection; Psoriatic arthritis

Indexed keywords

AGED; ALANINE TRANSAMINASE; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL PRODUCTS; FEMALE; HEPATITIS C; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD;

EID: 84893932253     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2378-0     Document Type: Article

References (20)

1. Moll JM, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3:55-78
2. Scarpa R, Manguso F, D'Arienzo A, D'Armiento FP, Astarita C, Mazzacca G, Ayala F (2000) Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. J Rheumatol 27:1241-1246
3. Costa L, Caso F, D'Elia L, Atteno M, Peluso R, Del Puente A, Strazzullo P, Scarpa R (2012) Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol 31:711-715
4. Scarpa R, Atteno M, Lubrano E, Provenzano G, D'Angelo S, Spadaro A, Costa L, Olivieri I (2011) The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study. Clin Rheumatol 30:1063-1067
5. Punzi L, Podswiadek M, Sfriso P, Oliviero F, Fiocco U, Todesco S (2007) Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis. Autoimmun Rev 6:524-528
6. Modesti V, Ramonda R, Ortolan A, Lorenzin M, Lo Nigro A, Frallonardo P, Oliviero F, Campana C, Punzi L (2012) Infection relapse in spondyloarthritis treated with biological drugs: a single-centre study. Scand J Rheumatol 41:490-491
7. Fabris P, Baldo V, Baldovin T, Bellotto E, Rassu M, Trivello R, Tramarin A, Tositti G, Floreani A (2008) Changing epidemiology of HCV and HBV infections in Northern Italy: a survey in the general population. J Clin Gastroenterol 42:527-532
8. Cavazzana I, Ceribelli A, Cattaneo R, Franceschini F (2008) Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. Autoimmun Rev 8:104-106
9. Rokhsar C, Rabhan N, Cohen SR (2006) Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection. J Am Acad Dermatol 54:361-362
10. Magliocco MA, Gottlieb AB (2004) Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 51:580-584
11. Aslanidis S, Vassiliadis T, Pyrpasopoulou A, Douloumpakas I, Zamboulis C (2007) Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases. Clin Rheumatol 26:261-264
12. Calabrese LH, Zein N (2007) Biologic agents and liver toxicity: an added concern or therapeutic opportunity? Nat Clin Pract Rheumatol 3:422-423
13. Salvarani C, Olivieri I, Pipitone N, Cantini F, Marchesoni A, Punzi L, Scarpa R, Matucci-Cerinic M; Italian Society for Rheumatology (2011) Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology. Clin Exp Rheumatol 29:S28-S41
14. Park J, Kang W, Ryu SW, Kim WI, Chang DY, Lee DH, do Park Y, Choi YH, Choi K, Shin EC, Choi C (2012) Hepatitis C virus infection enhances TNFα-induced cell death via suppression of NF-κB. Hepatology 56:831-840
15. Suryaprasad AG, Prindiville T (2003) The biology of TNF blockade. Autoimmun Rev 2:346-357
16. Tilg H, Wilmer A, Vogel W, Herold M, Nölchen B, Judmaier G, Huber C (1992) Serum levels of cytokines in chronic liver diseases. Gastroenterology 103:264-274
17. Freeman AJ, Marinos G, Ffrench RA, Lloyd AR (2001) Immunopathogenesis of hepatitis C virus infection. Immunol Cell Biol 79:515-536
18. Larrea E, Garcia N, Qian C, Civeira MP, Prieto J (1996) Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology 23:210-217
19. Aletaha D, Kapral T, Smolen JS (2003) Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. Ann Rheum Dis 62:482-486
20. Galeazzi M, Bellisai F, Giannitti C, Manganelli S, Morozzi G, Sebastiani GD (2007) Safety of cyclosporin A in HCV-infected patients: experience with cyclosporin A in patients affected by rheumatological disorders and concomitant HCV infection. Ann N Y Acad Sci 1110:544-549